Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
FRAZIER KENNETH C | Chairman, President & CEO | Nov 09 | Sale | 81.42 | 280,000 | 22,797,011 | 411,546 | Nov 12 04:45 PM | Nally Michael | EVP, Chief Marketing Officer | Oct 30 | Option Exercise | 75.89 | 2,287 | 173,560 | 13,403 | Nov 03 04:48 PM | MIZELL STEVEN | EVP, Chief HR Officer | Oct 30 | Option Exercise | 75.89 | 4,574 | 347,121 | 7,624 | Nov 03 04:44 PM | Clyburn Frank | EVP, Chief Commercial Officer | Oct 30 | Option Exercise | 75.89 | 2,287 | 173,560 | 83,656 | Nov 03 04:55 PM | Davis Robert M | EVP, Global Svcs & CFO | Oct 05 | Option Exercise | 0.00 | 251,273 | 0 | 422,329 | Oct 06 04:52 PM | Davis Robert M | EVP, Global Svcs & CFO | Oct 05 | Sale | 81.03 | 251,273 | 20,360,325 | 171,056 | Oct 06 04:52 PM | Chattopadhyay Sanat | Exe V-P & Pres. MMD | Aug 13 | Sale | 83.01 | 10,380 | 861,676 | 67,373 | Aug 17 06:36 PM | Clyburn Frank | EVP, Chief Commercial Officer | Aug 05 | Option Exercise | 0.00 | 18,876 | 0 | 99,639 | Aug 06 04:53 PM | Clyburn Frank | EVP, Chief Commercial Officer | Aug 05 | Sale | 81.55 | 18,876 | 1,539,274 | 80,763 | Aug 06 04:53 PM | Gerberding Julie L. | EVP Strat Comm, GI Pub Policy | Jul 17 | Option Exercise | 0.00 | 18,111 | 0 | 62,862 | Jul 20 04:53 PM | Gerberding Julie L. | EVP Strat Comm, GI Pub Policy | Jul 17 | Sale | 80.00 | 36,285 | 2,902,976 | 26,577 | Jul 20 04:53 PM | BRUN LESLIE A | Director | May 07 | Option Exercise | 0.00 | 5,000 | 0 | 6,948 | May 07 04:48 PM | WEEKS WENDELL P | Director | May 07 | Option Exercise | 0.00 | 5,000 | 0 | 5,100 | May 07 04:50 PM | WEEKS WENDELL P | Director | May 07 | Sale | 76.02 | 5,000 | 380,104 | 100 | May 07 04:50 PM | BRUN LESLIE A | Director | May 07 | Sale | 75.46 | 5,000 | 377,300 | 1,948 | May 07 04:48 PM | Nally Michael | EVP, Chief Marketing Officer | May 05 | Option Exercise | 76.86 | 2,345 | 180,237 | 12,054 | May 06 05:14 PM | Karachun Rita A | Sr. VP Fince-Global Controller | May 05 | Option Exercise | 76.86 | 3,283 | 252,331 | 29,401 | May 06 05:15 PM | Fleming Michael | SVP Chief Ethics & Com Officer | May 05 | Option Exercise | 76.86 | 1,290 | 99,149 | 7,304 | May 06 05:16 PM | Clyburn Frank | EVP, Chief Commercial Officer | May 05 | Option Exercise | 76.86 | 3,752 | 288,379 | 82,611 | May 06 05:17 PM | Clyburn Frank | EVP, Chief Commercial Officer | May 04 | Option Exercise | 77.67 | 1,904 | 147,884 | 79,797 | May 06 05:17 PM | Fleming Michael | SVP Chief Ethics & Com Officer | May 04 | Option Exercise | 77.67 | 692 | 53,748 | 6,252 | May 06 05:16 PM | Karachun Rita A | Sr. VP Fince-Global Controller | May 04 | Option Exercise | 77.67 | 1,212 | 94,136 | 26,715 | May 06 05:15 PM | Zachary Jennifer | EVP, General Counsel | May 04 | Option Exercise | 77.67 | 5,772 | 448,311 | 9,489 | May 06 05:13 PM | Nally Michael | EVP, Chief Marketing Officer | May 04 | Option Exercise | 77.67 | 1,298 | 100,816 | 10,274 | May 06 05:14 PM | Karachun Rita A | Sr. VP Fince-Global Controller | May 03 | Option Exercise | 77.67 | 875 | 67,961 | 25,934 | May 05 04:48 PM | Fleming Michael | SVP Chief Ethics & Com Officer | May 03 | Option Exercise | 77.67 | 1,541 | 119,689 | 6,089 | May 05 04:42 PM |
|